WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.
The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen’s Imdelltra (tarlatamab-dlle), reducing the recommended monitoring time for patients with extensive-stage small cell lung cancer (ES-SCLC) after their first two infusions.
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Etcamah (camizestrant), used with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib), for breast cancer.
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).
Kazia Therapeutics has closed an oversubscribed public offering that could provide the company with up to $120m in gross proceeds if all milestone-linked warrants are exercised, aimed primarily at funding clinical development of paxalisib.
US-based healthcare services provider McKesson has agreed to buy Precision Medicine Group for $2.25bn.
The European Commission (EC) has approved an extended use of Johnson & Johnson’s Tecvayli (teclistamab), along with daratumumab, to treat adult patients with relapsed or refractory multiple myeloma (r/r MM).
WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration, aiming to widen patient access to advanced care, clinical expertise, and research initiatives throughout central Pennsylvania, US.
BeOne Medicines, the BeOne Care Foundation, and The Max Foundation have extended their partnership to expand Brukinsa (zanubrutinib) access for chronic lymphocytic leukaemia (CLL) treatment in low- and middle-income countries until 2028.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.